Related references
Note: Only part of the references are listed.Interim results from a phase Ib/II study of pepinemab in combination with avelumab in advanced NSCLC patients following progression on prior systemic and/or anti-PDx therapies.
Michael Rahman Shafique et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
A phase Ib study of combination of avelumab and taxane-based chemotherapy in platinum refractory or ineligible metastatic urothelial cancer (AVETAX study).
Rohan Garje et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Current Strategies to Target Tumor-Associated-Macrophages to Improve Anti-Tumor Immune Responses
Clement Anfray et al.
CELLS (2020)
The future of cancer immunotherapy: microenvironment-targeting combinations
Yonina R. Murciano-Goroff et al.
CELL RESEARCH (2020)
Maintenance avelumab + best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase III interim analysis.
Thomas Powles et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Immunomodulatory Roles of VEGF Pathway Inhibitors in Renal Cell Carcinoma
Laure Hirsch et al.
DRUGS (2020)
First-Line Management of Advanced High-Grade Serous Ovarian Cancer
Reem D. Mahmood et al.
CURRENT ONCOLOGY REPORTS (2020)
Finding the hot spot: identifying immune sensitive gastrointestinal tumors
Andre Luiz Pitanga Bastos De Souza
TRANSLATIONAL GASTROENTEROLOGY AND HEPATOLOGY (2020)
Combined cytotoxic chemotherapy and immunotherapy of cancer: modern times
Christian Bailly et al.
NAR CANCER (2020)
Rationale and design of the POLEM trial: avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III mismatch repair deficient or POLE exonuclease domain mutant colon cancer: a phase III randomised study
David Lau et al.
ESMO OPEN (2020)
Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma
Elie Rassy et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2020)
Immune checkpoint inhibitors and non-small-cell lung cancer management: 2018 update
Omar Abdel-Rahman et al.
IMMUNOTHERAPY (2019)
Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
Xin Wang et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Brian I. Rini et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Reactive oxygen species modulate macrophage immunosuppressive phenotype through the up-regulation of PD-L1
Cecilia Roux et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer Phase 1b Results From the JAVELIN Solid Tumor Trial
Mary L. Disis et al.
JAMA ONCOLOGY (2019)
Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study
U. A. Matulonis et al.
ANNALS OF ONCOLOGY (2019)
Autoimmune Endocrine Dysfunctions Associated with Cancer Immunotherapies
Silvia Martina Ferrari et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Biomarker analyses from JAVELIN Renal 101: Avelumab plus axitinib (A plus Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC).
Toni K. Choueiri et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432
F. Wang et al.
ANNALS OF ONCOLOGY (2019)
Let's Raise a Glass to Sydney In Memoriam (1927-2019) Obituary
Ronald M. Evans
CANCER RESEARCH (2019)
Avelumab alone or in combination with pegylated liposomal doxorubicin versus pegylated liposomal doxorubicin alone in platinum-resistant or refractory epithelial ovarian cancer: Primary and biomarker analysis of the phase III JAVELIN Ovarian 200 trial
E. Pujade-Lauraine et al.
GYNECOLOGIC ONCOLOGY (2019)
Supplementary granulocyte macrophage colony-stimulating factor to chemotherapy and programmed death-ligand 1 blockade decreases local recurrence after surgery in bladder cancer
Makito Miyake et al.
CANCER SCIENCE (2019)
Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma
Laurence Albiges et al.
EUROPEAN UROLOGY (2019)
An update on immunotherapy options for urothelial cancer
Burak Bilgin et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2019)
Drug-induced PD-L1 expression and cell stress response in breast cancer cells can be balanced by drug combination
Yosi Gilad et al.
SCIENTIFIC REPORTS (2019)
Domatinostat favors the immunotherapy response by modulating the tumor immune microenvironment (TIME)
Anne Catherine Bretz et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Avelumab monotherapy as first-line or second-line treatment in patients with metastatic renal cell carcinoma: phase Ib results from the JAVELIN Solid Tumor trial
Ulka Vaishampayan et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Arrested Developments: CDK4/6 Inhibitor Resistance and Alterations in the Tumor Immune Microenvironment
Jessica L. F. Teh et al.
CLINICAL CANCER RESEARCH (2019)
Phase I study of domatinostat (4SC-202), a class I histone deacetylase inhibitor in patients with advanced hematological malignancies
Bastian von Tresckow et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2019)
Autocrine VEGF signalling on M2 macrophages regulates PD-L1 expression for immunomodulation of T cells
Yin-Siew Lai et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2019)
Cisplatin-induced immune modulation in ovarian cancer mouse models with distinct inflammation profiles
Shannon Grabosch et al.
ONCOGENE (2019)
Product review: avelumab, an anti-PD-L1 antibody
Julie M. Collins et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2019)
Importance of semaphorins in cancer immunity
Li-Han Chen et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2019)
JAVELIN ovarian PARP 100 study design: Phase III trial of avelumab plus chemotherapy followed by avelumab plus talazoparib maintenance in previously untreated epithelial ovarian cancer.
Ramez Nassef Eskander et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Results from a meta-analysis of immune checkpoint inhibitors in first-line renal cancer patients: does PD-L1 matter?
Giandomenico Roviello et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2019)
Efficacy of chemotherapy or chemo-anti-PD-1 combination after failed anti-PD-1 therapy for relapsed and refractory hodgkin lymphoma: A series from lysa centers
Cedric Rossi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Recent advances in colony stimulating factor-1 receptor/c-FMS as an emerging target for various therapeutic implications
Archana Kumari et al.
BIOMEDICINE & PHARMACOTHERAPY (2018)
Vinorelbine, cyclophosphamide and 5-FU effects on the circulating and intratumoural landscape of immune cells improve anti-PD-L1 efficacy in preclinical models of breast cancer and lymphoma
Stefania Orecchioni et al.
BRITISH JOURNAL OF CANCER (2018)
Crosstalk between VEGFR and other receptor tyrosine kinases for TKI therapy of metastatic renal cell carcinoma
Yongchang Lai et al.
CANCER CELL INTERNATIONAL (2018)
Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non-Small Cell Lung Cancer
Song Ee Park et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial
Manish R. Patel et al.
LANCET ONCOLOGY (2018)
Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial
Toni K. Choueiri et al.
LANCET ONCOLOGY (2018)
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
David F. McDermott et al.
NATURE MEDICINE (2018)
Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa
Kabir A. Khan et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L. Gandhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
PD-L1 inhibition with avelumab for metastatic Merkel cell carcinoma
Maria Rita Gaiser et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2018)
PD-1/PD-L1 pathway: an adaptive immune resistance mechanism to immunogenic chemotherapy in colorectal cancer
Magalie Dosset et al.
ONCOIMMUNOLOGY (2018)
Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300
Y. -J. Bang et al.
ANNALS OF ONCOLOGY (2018)
Ipilimumab in combination with nivolumab for the treatment of renal cell carcinoma
Xin Gao et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2018)
Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study
Fabrice Barlesi et al.
LANCET ONCOLOGY (2018)
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Spencer C. Wei et al.
CANCER DISCOVERY (2018)
Immune checkpoint inhibitors: recent progress and potential biomarkers
Pramod Darvin et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2018)
Targeting B7-H1 (PD-L1) sensitizes cancer cells to chemotherapy
Xiaosheng Wu et al.
HELIYON (2018)
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
Luc Y. Dirix et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
Gemcitabine Synergizes with Immune Checkpoint Inhibitors and Overcomes Resistance in a Preclinical Model and Mesothelioma Patients
Paulino Tallon de lara et al.
CLINICAL CANCER RESEARCH (2018)
Avelumab: combining immune checkpoint inhibition and antibody-dependent cytotoxicity
Gerhard Hamilton et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2017)
PDL-1/PD1 inhibitors: antibody or antinobody?
Fouad Aoun et al.
FUTURE ONCOLOGY (2017)
Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade
Martina Schmittnaegel et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Merkel cell carcinoma
Juergen C. Becker et al.
NATURE REVIEWS DISEASE PRIMERS (2017)
Renal cell carcinoma
James J. Hsieh et al.
NATURE REVIEWS DISEASE PRIMERS (2017)
Epidemiology of ovarian cancer: a review
Brett M. Reid et al.
CANCER BIOLOGY & MEDICINE (2017)
Evolving Treatment of Advanced Urothelial Cancer
Srikala S. Sridhar
JOURNAL OF ONCOLOGY PRACTICE (2017)
IMmotion150: A phase II trial in untreated metastatic renal cell carcinoma (mRCC) patients (pts) of atezolizumab (atezo) and bevacizumab (bev) vs and following atezo or sunitinib (sun).
Michael B. Atkins et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Predictors of chemotherapy efficacy in non-small-cell lung cancer: a challenging landscape
K. A. Olaussen et al.
ANNALS OF ONCOLOGY (2016)
Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges
Chrisann Kyi et al.
IMMUNOTHERAPY (2016)
Safety, PD-L1 expression, and clinical activity of avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with advanced gastric or gastroesophageal junction cancer.
Hyun Cheol Chung et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial
Howard L. Kaufman et al.
LANCET ONCOLOGY (2016)
The ratio of CD8 to Treg tumor-infiltrating lymphocytes is associated with response to cisplatin-based neoadjuvant chemotherapy in patients with muscle invasive urothelial carcinoma of the bladder
Alexander S. Baras et al.
ONCOIMMUNOLOGY (2016)
The Role of Myeloid-Derived Suppressor Cells in Patients with Solid Tumors: A Meta-Analysis
Shuo Zhang et al.
PLOS ONE (2016)
Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?
L. Apetoh et al.
ANNALS OF ONCOLOGY (2015)
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Suzanne L. Topalian et al.
CANCER CELL (2015)
Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression via the Nuclear Factor-κB to Foster an Immunosuppressive Tumor Microenvironment in Ovarian Cancer
Jin Peng et al.
CANCER RESEARCH (2015)
VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors
Thibault Voron et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2015)
The future of immune checkpoint therapy
Padmanee Sharma et al.
SCIENCE (2015)
Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis
Bin Shang et al.
SCIENTIFIC REPORTS (2015)
Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells
Benjamin Boyerinas et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Doxil Synergizes with Cancer Immunotherapies to Enhance Antitumor Responses in Syngeneic Mouse Models
Jonathan Rios-Doria et al.
NEOPLASIA (2015)
Axitinib for the treatment of advanced renal cell carcinoma
Hideyuki Akaza et al.
EXPERT OPINION ON PHARMACOTHERAPY (2014)
Chemotherapeutics and Radiation Stimulate MHC Class I Expression through Elevated Interferon-beta Signaling in Breast Cancer Cells
Shan Wan et al.
PLOS ONE (2012)
Immune-potentiating effects chemotherapeutic drug of the cyclophosphamide
Sven Brode et al.
CRITICAL REVIEWS IN IMMUNOLOGY (2008)
Share Paper
